FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
update
/
details

Velsera and Diagnostic Longwood Partner to Accelerate Precision Medicine in Spain and Portugal

NextEdge Admin

09 Oct 2024

2 min 14 sec

Next-Generation Sequencing,Diagnostic Longwood,Precision Medicine

Velsera, a global healthcare technology leader, has partnered with Diagnostic Longwood, a key distributor of Next-Generation Sequencing (NGS) solutions in the Iberian market, to accelerate the adoption of precision medicine in Spain and Portugal. This collaboration integrates Velsera's Clinical Genomics Workspace (CGW) platform with Diagnostic Longwood's established regional expertise and distribution network.

"We are thrilled to partner with Velsera to bring advanced genomics solutions to the Iberian market," said Rosario Sanches, Chief Scientific Officer at Diagnostic Longwood. "Together, we aim to empower healthcare providers with NGS technology that will drive precision medicine and improve patient care across the region."

The partnership will leverage Velsera's CGW platform, which streamlines NGS workflows, enabling clinical laboratories to efficiently analyze genetic data for oncology and inherited diseases. Combined with Diagnostic Longwood's distribution reach and local knowledge, this collaboration will provide healthcare providers with a robust, integrated solution for gene fusion analysis and NGS data interpretation.

"Partnering with Diagnostic Longwood allows us to connect with more healthcare providers, ensuring faster and more accurate precision treatments for patients," said Rakesh Nagarajan, MD, PhD, Chief Medical Officer at Velsera. "Their market leadership is essential to advancing our technology in clinical practice across Spain and Portugal."

This strategic alliance underscores both companies' commitment to advancing healthcare through innovation and collaboration, ensuring timely and accurate treatments that improve patient outcomes across the region.